
zzso zzso zzso zzso Company, Princeton, zzso has been studied primarily on a zzso schedule as a zzso zzso or zzso infusion at doses ranging from 135 to 250 zzso The observed toxicity profile seems to be both dose and schedule zzso zzso zzso of zzso given weekly over 6 weeks on a zzso schedule for an overall increase in dose intensity was thought to improve the therapeutic index of zzso in a variety of advanced zzso and to be suitable for zzso zzso For this study, chemotherapy consisted of a weekly zzso infusion of zzso at a starting dose of 40 zzso for 6 weeks, followed by a zzso to zzso zzso zzso dosage was escalated in 10 zzso increments in subsequent patients, to a maximum dosage of 90 zzso zzso zzso zzso zzso and zzso were administered immediately before the zzso zzso Fifty patients participated in the zzso The male to female ratio was 21 to 29, the median age was zzso years (age range, 33 to zzso and the median performance status was zzso All patients were zzso zzso zzso response included five complete responses zzso 15 partial responses zzso 19 no change zzso and 11 disease zzso zzso Median dose intensity was 410 zzso zzso zzso 200 to 540 zzso zzso Hematologic toxicity was mild, with no grade 3 or 4 toxicity up to 90 zzso No hypersensitivity reactions or zzso or cardiac zzso were zzso zzso weekly zzso is concluded to be active in a variety of zzso tumor zzso The overall low zzso and peripheral toxicity profile suggests that further dose zzso of weekly zzso and/or combination with other zzso agents zzso zzso zzso zzso may be zzso zzso can be given safely in the zzso zzso zzso 90 zzso is recommended for zzso zzso zzso zzso may be considered a valuable and promising alternative to standard zzso treatment, with further options possible in combination zzso 

